[{"id":"c1bed97e-11d6-4bc0-9436-ed6e5ea85e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03222674","created_at":"2021-01-18T15:54:20.717Z","updated_at":"2024-07-02T16:37:06.013Z","phase":"Phase 1/2","brief_title":"Multi-CAR T Cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT03222674","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • NCAM1 • IL3RA","pipe":"","alterations":" ","tags":["CD38 • CD33 • NCAM1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2018-10-17"}]